Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Gallo

Showing results (11-20 of 62) with videos related to

Pageof 7
Sort By:
European Journal of Immunology|February 9, 2010
The antimicrobial peptide LL-37 modulates the inflammatory and host defense response of human neutrophilsSadek M Alalwani, Johannes Sierigk, Christian Herr, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|June 5, 2009
A first-in-man study of percutaneous myocardial cryotreatment in nonrevascularizable patients with refractory anginaRichard Gallo, Paul Fefer, Michael Freeman, et al.
International Journal of Cardiology|March 20, 2010
Development and validation of a bleeding risk model for patients undergoing elective percutaneous coronary interventionGilles Montalescot, Genevieve Salette, Gabriel Steg, et al.
Emerging Infectious Diseases|October 27, 2004
Laboratory-acquired brucellosisStephanie Noviello, Richard Gallo, Molly Kelly, et al.
American Heart Journal|January 28, 2010
Hematomas of at least 5 cm and outcomes in patients undergoing elective percutaneous coronary intervention: insights from the SafeTy and Efficacy of Enoxaparin in PCI patients, an internationaL randomized Evaluation (STEEPLE) trialHarvey D White, Philip E Aylward, Richard Gallo, et al.
American Heart Journal|December 17, 2008
The use of intravenous enoxaparin in elective percutaneous coronary intervention in patients with renal impairment: results from the SafeTy and Efficacy of Enoxaparin in PCI patients, an internationaL randomized Evaluation (STEEPLE) trialHarvey D White, Richard Gallo, Marc Cohen, et al.
American Heart Journal|December 18, 2007
Guideline adjudicated fibrinolytic failure: incidence, findings, and management in a contemporary clinical trialChristopher E Buller, Robert C Welsh, Cynthia M Westerhout, et al.
Journal of Interventional Cardiology|March 21, 2009
Determining the in-hospital cost of bleeding in patients undergoing percutaneous coronary interventionEdward F Ewen, Liping Zhao, Paul Kolm, et al.
American Journal of Physiology. Heart and Circulatory Physiology|December 18, 2002
In vivo measurement of coronary circulation angiotensin-converting enzyme activity in humansCezar Staniloae, Andreas J Schwab, Andre Simard, et al.
The Canadian Journal of Cardiology|May 11, 2006
Catheter thrombosis during primary percutaneous coronary intervention for acute ST elevation myocardial infarction despite subcutaneous low-molecular-weight heparin, acetylsalicylic acid, clopidogrel and abciximab pretreatmentChristopher E Buller, Gordon E Pate, Paul W Armstrong, et al.
Pageof 7

Showing results (11-20 of 62) with videos related to

Sort By:
Pageof 7
European Journal of Immunology|February 9, 2010
The antimicrobial peptide LL-37 modulates the inflammatory and host defense response of human neutrophilsSadek M Alalwani, Johannes Sierigk, Christian Herr, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|June 5, 2009
A first-in-man study of percutaneous myocardial cryotreatment in nonrevascularizable patients with refractory anginaRichard Gallo, Paul Fefer, Michael Freeman, et al.
International Journal of Cardiology|March 20, 2010
Development and validation of a bleeding risk model for patients undergoing elective percutaneous coronary interventionGilles Montalescot, Genevieve Salette, Gabriel Steg, et al.
Emerging Infectious Diseases|October 27, 2004
Laboratory-acquired brucellosisStephanie Noviello, Richard Gallo, Molly Kelly, et al.
American Heart Journal|January 28, 2010
Hematomas of at least 5 cm and outcomes in patients undergoing elective percutaneous coronary intervention: insights from the SafeTy and Efficacy of Enoxaparin in PCI patients, an internationaL randomized Evaluation (STEEPLE) trialHarvey D White, Philip E Aylward, Richard Gallo, et al.
American Heart Journal|December 17, 2008
The use of intravenous enoxaparin in elective percutaneous coronary intervention in patients with renal impairment: results from the SafeTy and Efficacy of Enoxaparin in PCI patients, an internationaL randomized Evaluation (STEEPLE) trialHarvey D White, Richard Gallo, Marc Cohen, et al.
American Heart Journal|December 18, 2007
Guideline adjudicated fibrinolytic failure: incidence, findings, and management in a contemporary clinical trialChristopher E Buller, Robert C Welsh, Cynthia M Westerhout, et al.
Journal of Interventional Cardiology|March 21, 2009
Determining the in-hospital cost of bleeding in patients undergoing percutaneous coronary interventionEdward F Ewen, Liping Zhao, Paul Kolm, et al.
American Journal of Physiology. Heart and Circulatory Physiology|December 18, 2002
In vivo measurement of coronary circulation angiotensin-converting enzyme activity in humansCezar Staniloae, Andreas J Schwab, Andre Simard, et al.
The Canadian Journal of Cardiology|May 11, 2006
Catheter thrombosis during primary percutaneous coronary intervention for acute ST elevation myocardial infarction despite subcutaneous low-molecular-weight heparin, acetylsalicylic acid, clopidogrel and abciximab pretreatmentChristopher E Buller, Gordon E Pate, Paul W Armstrong, et al.
Pageof 7